Free shipping on all orders over $ 500

Bezuclastinib

Cat. No. M28692
Bezuclastinib Structure
Synonym:

CGT9486; PLX 9486

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 < IC50 < 1 μM). Bezuclastinib is a tyrosine kinase inhibitor.

Chemical Information
Molecular Weight 331.37
Formula C19H17N5O
CAS Number 1616385-51-3
Form Solid
Solubility (25°C) DMSO 75 mg/mL (ultrasonic)
Storage 4°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jason Gotlib. Hematology Am Soc Hematol Educ Program. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms

[2] Andreas Reiter, et al. Leukemia. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

[3] Andreas Reiter, et al. Blood Adv. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

[4] Daniel J DeAngelo, et al. Nat Med. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

[5] Jason Gotlib, et al. Nat Med. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

Related c-Kit Products
Labuxtinib

Labuxtinib is c-kit tyrosine kinase inhibitor.

Elenestinib phosphate

Elenestinib phosphate (BLU-263 phosphate) is a potent and orally active tyrosine kinase inhibitor. Elenestinib phosphate has the potential for the research of systemic mastocytosis (SM).

Elenestinib

Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor. Elenestinib has the potential for the research of systemic mastocytosis (SM).

Amuvatinib hydrochloride

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.

c-Kit-IN-5-1 

c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties.

  Catalog
Abmole Inhibitor Catalog




Keywords: Bezuclastinib, CGT9486; PLX 9486 supplier, c-Kit, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.